country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P10301

Copy Link Print Information

CXCL9(74-103)

Name: CXCL9(74-103)
Brand: MedChemExpress
SKU: HY-P10301
Availability: PreOrder

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

CXCL9(74-103) is a derivative peptide of CXCL9 that has a high affinity for glycosaminoglycans (GAGs) and can bind to GAGs. CXCL9(74-103) possesses anti-angiogenic properties, capable of reducing EGF, VEGF165, and FGF-2-mediated angiogenesis processes in vitro, without exhibiting cytotoxicity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Formel: C₁₅₈H₂₉₅N₅₉O₄₀
Molecular Weight:3661.40

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

CXCL9(74-103) Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle CXCR Isoform-spezifische Produkte anzeigen :

In Vitro

CXCL9(74-103) (0.3-3 μM; 3-4 days) reduces growth factor-induced endothelial cell proliferation, migration, (0.3-3 μM; 15 min) adhesion, and spheroid sprouting in HMVECs. CXCL9(74-103) (0.3-3 μM; 24 h) is not cytotoxic in HMVECs^[1].
CXCL9(74-103) (3 μM) interferes with growth factor signaling by reducing VEGF165 binding to HS and directly binding to FGF-2, and relies on cell surface HS binding to endothelial cells to exert its anti-angiogenic activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

CXCL9(74-103) (subcutaneously implanted osmotic pump containing 400 µg/100 µL) significantly reduces FGF-2-induced Matrigel plug angiogenesis in C57BL/6 mice. CXCL9(74-103) (administered as 10 μL drops of 100 μg/mL, once daily for 4 days) reduces pathological blood vessel growth in the corneal burn model of C57BL/6 mice. CXCL9(74-103) (subcutaneously implanted osmotic pump containing 800 µg/100 µL, delivering a continuous dose over the course of two weeks) attenuates tumor angiogenesis in MDA-MB-231 breast cancer SCID mice. Additionally, CXCL9(74-103) also reduces vascular leakage in the retina of diabetic rats, demonstrating its anti-angiogenic effect^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

Molecular Weight 3661.40
Formel C₁₅₈H₂₉₅N₅₉O₄₀
Sequence

Lys-Lys-Lys-Gln-Lys-Asn-Gly-Lys-Lys-His-Gln-Lys-Lys-Lys-Val-Leu-Lys-Val-Arg-Lys-Ser-Gln-Arg-Ser-Arg-Gln-Lys-Lys-Thr-Thr
Sequence Shortening

KKKQKNGKKHQKKKVLKVRKSQRSRQKKTT
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (1)

All

Sort by:

Journal Impact Factor

Cell Death Dis

Ripk2 promotes CD8+ T cell inactivation and hepatocellular carcinoma progression through Myb/Cxcl9 and Pax5/Adpgk signaling pathways. [Abstract]

2026 May 29. PMID: 42215445

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (260 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. De Zutter A, et al. The Chemokine-Based Peptide, CXCL9(74-103), Inhibits Angiogenesis by Blocking Heparan Sulfate Proteoglycan-Mediated Signaling of Multiple Endothelial Growth Factors. Cancers (Basel). 2021;13(20):5090. Published 2021 Oct 12. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

CXCL9(74-103)

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CXCL9(74-103)

Publications Citing Use of MedChemExpress (MCE) CXCL9(74-103)

Alle CXCR Isoform-spezifische Produkte anzeigen